Lars Egevad
About
Lars Egevad is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Rheumatology.
According to data from OpenAlex, Lars Egevad has authored 336 papers receiving a total of 18.5k indexed citations (citations by other indexed papers that have themselves been cited), including 255 papers in Pulmonary and Respiratory Medicine, 83 papers in Surgery and 79 papers in Rheumatology. Recurrent topics in Lars Egevad's work include Prostate Cancer Treatment and Research (191 papers), Prostate Cancer Diagnosis and Treatment (186 papers) and Urologic and reproductive health conditions (77 papers). Lars Egevad is often cited by papers focused on Prostate Cancer Treatment and Research (191 papers), Prostate Cancer Diagnosis and Treatment (186 papers) and Urologic and reproductive health conditions (77 papers). Lars Egevad collaborates with scholars based in Sweden, United States and New Zealand. Lars Egevad's co-authors include Brett Delahunt, Jonathan I. Epstein, John R. Srigley, Peter A. Humphrey, Mahul B. Amin, Rodolfo Montironi, Pär Stattin, Anders Bergh, David J. Grignon and Hemamali Samaratunga and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nature Communications.
In The Last Decade
Lars Egevad
326 papers receiving 18.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Lars Egevad Sweden | 65 | 12.3k | 5.5k | 3.3k | 3.2k | 3.1k | 336 | 18.5k | ||
| Peter A. Humphrey United States | 80 | 15.5k 1.3× | 7.7k 1.4× | 5.4k 1.6× | 4.9k 1.5× | 3.6k 1.2× | 362 | 26.5k | ||
| Theodorus van der Kwast Netherlands | 86 | 20.0k 1.6× | 8.2k 1.5× | 5.1k 1.5× | 4.4k 1.4× | 4.4k 1.4× | 651 | 32.9k | ||
| Rodolfo Montironi Italy | 77 | 16.3k 1.3× | 9.7k 1.8× | 5.9k 1.8× | 4.3k 1.3× | 5.0k 1.6× | 877 | 30.3k | ||
| Lawrence D. True United States | 61 | 8.0k 0.6× | 6.1k 1.1× | 3.5k 1.1× | 1.2k 0.4× | 3.3k 1.1× | 277 | 15.9k | ||
| Rajal B. Shah United States | 55 | 8.9k 0.7× | 7.6k 1.4× | 2.5k 0.7× | 1.1k 0.3× | 3.9k 1.3× | 153 | 14.9k | ||
| Arndt Hartmann Germany | 76 | 4.9k 0.4× | 8.7k 1.6× | 6.0k 1.8× | 1.1k 0.3× | 4.5k 1.4× | 715 | 21.0k | ||
| Antonio López-Beltrán Spain | 63 | 7.0k 0.6× | 5.6k 1.0× | 3.5k 1.1× | 1.8k 0.6× | 2.7k 0.9× | 537 | 16.5k | ||
| Patricia Troncoso United States | 62 | 8.0k 0.6× | 3.9k 0.7× | 4.4k 1.3× | 1.8k 0.6× | 2.5k 0.8× | 256 | 13.8k | ||
| David J. Grignon United States | 76 | 14.6k 1.2× | 6.0k 1.1× | 3.5k 1.1× | 3.1k 1.0× | 3.7k 1.2× | 364 | 20.8k | ||
| Jiaoti Huang United States | 72 | 8.2k 0.7× | 7.3k 1.3× | 4.3k 1.3× | 1.3k 0.4× | 3.8k 1.2× | 308 | 16.4k |
Countries citing papers authored by Lars Egevad
Since
Specialization
Citations
This map shows the geographic impact of Lars Egevad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Egevad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Egevad more than expected).
Fields of papers citing papers by Lars Egevad
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Lars Egevad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Egevad. The network helps show where Lars Egevad may publish in the future.
Co-authorship network of co-authors of Lars Egevad
This figure shows the co-authorship network connecting the top 25 collaborators of Lars Egevad. A scholar is included among the top collaborators of Lars Egevad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lars Egevad. Lars Egevad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Kartasalo, Kimmo, et al.. (2025). Hierarchical Vision Transformers for prostate biopsy grading: Towards bridging the generalization gap. Medical Image Analysis. 105. 103663–103663.
2.
Gambacorta, Marcello, Einar Gudlaugsson, Svein Reidar Kjosavik, et al.. (2025). Artificial intelligence-assisted prostate cancer diagnosis for reduced use of immunohistochemistry. Communications Medicine. 5(1). 425–425.
3.
Egevad, Lars, et al.. (2025). The Role of Artificial Intelligence in the Evaluation of Prostate Pathology. Pathology International. 75(5). 213–220.
4.
Egevad, Lars, Martin Eklund, Theodorus van der Kwast, et al.. (2022). Use of the ISUP e-learning module improves interrater reliability in prostate cancer grading. Journal of Clinical Pathology. 77(1). 22–26.
5.
Egevad, Lars, Brett Delahunt, Hemamali Samaratunga, et al.. (2021). Interobserver reproducibility of perineural invasion of prostatic adenocarcinoma in needle biopsies. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 478(6). 1109–1116.
6.
Egevad, Lars, et al.. (2020). Benign mimics of prostate cancer. Pathology. 53(1). 26–35.
7.
Delahunt, Brett, Allison Steigler, Chris Atkinson, et al.. (2020). Perineural invasion by prostate adenocarcinoma in needle biopsies predicts bone metastasis: Ten year data from the TROG 03.04 RADAR Trial. Histopathology. 77(2). 284–292.
8.
Yaxley, John, Sheliyan Raveenthiran, François‐Xavier Nouhaud, et al.. (2019). Outcomes of Primary Lymph Node Staging of Intermediate and High Risk Prostate Cancer with 68Ga-PSMA Positron Emission Tomography/Computerized Tomography Compared to Histological Correlation of Pelvic Lymph Node Pathology: Can Preoperative 68Ga-PSMA Positron Emission Tomography/Computerized Tomography Replace Pelvic Lymph Node Dissection for Prostate Cancer Staging?. The Journal of Urology.
9.
Delahunt, Brett, Lars Egevad, David J. Grignon, John R. Srigley, & Hemamali Samaratunga. (2016). Prostate cancer grading: recent developments and future directions. British Journal of Urology. 117(S4). 7–8.
10.
Epstein, Jonathan I., Lars Egevad, Mahul B. Amin, et al.. (2015). The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. The American Journal of Surgical Pathology. 40(2). 244–252.
11.
Samaratunga, Hemamali, Brett Delahunt, Troy Gianduzzo, et al.. (2015). The prognostic significance of the 2014 International Society of Urological Pathology (ISUP) grading system for prostate cancer. Pathology. 47(6). 515–519.
12.
Moch, Holger, John R. Srigley, Brett Delahunt, et al.. (2014). Biomarkers in renal cancer. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 464(3). 359–365.
13.
Kristensen, Helle, Christa Haldrup, Siri H. Strand, et al.. (2014). Hypermethylation of the GABRE∼miR-452∼miR-224 Promoter in Prostate Cancer Predicts Biochemical Recurrence after Radical Prostatectomy. Clinical Cancer Research. 20(8). 2169–2181.
14.
Bruzzese, Francesca, Christina Hägglöf, Alessandra Leone, et al.. (2014). Local and Systemic Protumorigenic Effects of Cancer-Associated Fibroblast-Derived GDF15. Cancer Research. 74(13). 3408–3417.
15.
Seipel, Amanda H., Hemamali Samaratunga, Brett Delahunt, et al.. (2014). Immunohistochemical profile of ductal adenocarcinoma of the prostate. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 465(5). 559–565.
16.
Schultz, Niklas, et al.. (2013). Castration Therapy Results in Decreased Ku70 Levels in Prostate Cancer. Clinical Cancer Research. 19(6). 1547–1556.
17.
Iglesias‐Gato, Diego, Pernilla Wikström, Ning Jiang, et al.. (2013). SOCS2 mediates the cross talk between androgen and growth hormone signaling in prostate cancer. Carcinogenesis. 35(1). 24–33.
18.
Egevad, Lars, Roberta Mazzucchelli, & Rodolfo Montironi. (2012). Implications of the International Society of Urological Pathology Modified Gleason Grading System. Archives of Pathology & Laboratory Medicine. 136(4). 426–434.
19.
Hammarsten, Peter, Andreas Josefsson, Stina Häggström Rudolfsson, et al.. (2010). Low Levels of Phosphorylated Epidermal Growth Factor Receptor in Nonmalignant and Malignant Prostate Tissue Predict Favorable Outcome in Prostate Cancer Patients. Clinical Cancer Research. 16(4). 1245–1255.
20.
Srigley, John R., Mahul B. Amin, Liliane Boccon‐Gibod, et al.. (2005). Prognostic and predictive factors in prostate cancer: Historical perspectives and recent international consensus initiatives. Scandinavian Journal of Urology and Nephrology. 39(sup216). 8–19.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Peter A. Humphrey Breakdown of academic impact, for papers by Theodorus van der Kwast Breakdown of academic impact, for papers by Rodolfo Montironi Breakdown of academic impact, for papers by Lawrence D. True Breakdown of academic impact, for papers by Rajal B. Shah Breakdown of academic impact, for papers by Arndt Hartmann Breakdown of academic impact, for papers by Antonio López-Beltrán Breakdown of academic impact, for papers by Patricia Troncoso Breakdown of academic impact, for papers by David J. Grignon Breakdown of academic impact, for papers by Jiaoti Huang